New transplant combo aims to boost survival in blood cancer patients

NCT ID NCT07214688

Recruiting now Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a new combination of chemotherapy, radiation, and immune-suppressing drugs for people aged 18-65 with blood cancers who need a stem cell transplant. The goal is to see if this regimen improves survival one year after transplant. About 209 participants will receive the treatment at multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fludarabine, total body irradiation, cyclophosphamide, tacrolimus
What this could lead to: If successful, this could offer a safer and more effective stem cell transplant regimen for people with blood cancers, potentially improving survival rates.
What could go wrong: This is a phase 2 trial, so it's still early. The regimen may not improve survival and could cause serious side effects like infection or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 positive lymphoma myelodysplastic syndrome myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC STEM CELL TRANSPLANT RECIPIENT

Contacts and locations

Locations

John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
John Theurer Cancer Center at Jersey Shore University Medical Center
NOT_YET_RECRUITING

Neptune City, New Jersey, 07753, United States
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.